Last reviewed · How we verify

ST-100 (vezocolmitide) — Competitive Intelligence Brief

ST-100 (vezocolmitide) (ST-100 (vezocolmitide)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Wnt pathway inhibitor. Area: Oncology.

phase 3 Wnt pathway inhibitor Porcupine Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ST-100 (vezocolmitide) (ST-100 (vezocolmitide)) — ORA, Inc.. ST-100 (vezocolmitide) is a small molecule that modulates the Wnt/β-catenin signaling pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ST-100 (vezocolmitide) TARGET ST-100 (vezocolmitide) ORA, Inc. phase 3 Wnt pathway inhibitor Porcupine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Wnt pathway inhibitor class)

  1. ORA, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ST-100 (vezocolmitide) — Competitive Intelligence Brief. https://druglandscape.com/ci/st-100-vezocolmitide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: